Edition:
India

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

19.92EUR
1 Oct 2020
Change (% chg)

€0.08 (+0.40%)
Prev Close
€19.84
Open
€19.84
Day's High
€19.92
Day's Low
€19.84
Volume
545
Avg. Vol
7,057
52-wk High
€22.95
52-wk Low
€10.10

Latest Key Developments (Source: Significant Developments)

Carmat H1 Net Loss Narrows To 20.8 Million Euros
Wednesday, 9 Sep 2020 

Sept 9 (Reuters) - Carmat SA ::REPORTS ITS 2020 HALF-YEAR RESULTS AND ISSUES AN UPDATE ON ITS ACTIVITIES AND OUTLOOK.CASH POSITION OF €45.3 MILLION AT JUNE 30, 2020, COVERING THE NEXT MAJOR STAGES OF ITS PROJECT.DESPITE THE COVID-19 CRISIS, CARMAT STILL ON TRACK TO MEET KEY DEADLINES.H1 OF 2020 SAW A NET LOSS OF €20.8 MILLION, VERSUS A LOSS OF €24.0 MILLION AT JUNE 30, 2019, ONCE A FINANCIAL LOSS OF -€1.0 MILLION AND RESEARCH TAX CREDIT OF +€0.8 MILLION ARE TAKEN INTO ACCOUNT.AS ITS TOTAL ARTIFICIAL HEART PROJECT IS STILL IN CLINICAL DEVELOPMENT, CARMAT GENERATED NO SALES IN THE FIRST HALF OF 2020.IS CONTINUING TO CLOSELY MONITOR THE COVID-19 SITUATION IN FRANCE AND ABROAD AND, DEPENDING ON ITS EVOLUTION, MAY HAVE TO REASSESS ITS IMPACT AND ADJUST THE COMPANY’S DEVELOPMENT PROSPECTS.  Full Article

Carmat H1 Net Loss Widens To 24.0 Million Euros
Wednesday, 18 Sep 2019 

Sept 18 (Reuters) - CARMAT SA ::H1 NET LOSS EUR 24.0 MILLION VERSUS LOSS EUR 18.9 MILLION YEAR AGO.CASH POSITION OF €15.7 MILLION AT JUNE 30, 2019.H1 OPERATING LOSS EUR 23.7 MILLION VERSUS LOSS OF EUR 19.4 MILLION YEAR AGO.REAFFIRMS ITS MAIN DEVELOPMENT OBJECTIVES.  Full Article

Carmat Receives Approval To Resume Patient Enrollment In The PIVOTAL Study In Denmark
Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - CARMAT SA ::RECEIVES APPROVAL TO RESUME PATIENT ENROLLMENT IN THE PIVOTAL STUDY IN DENMARK.HAS RECEIVED APPROVAL OF DANISH HEALTH AUTHORITY AND ETHICAL COMMITTEE OF RIGSHOSPITALET HOSPITAL IN COPENHAGEN.IS CONTINUING DISCUSSIONS WITH COMPETENT AUTHORITIES IN KAZAKHSTAN AND CZECH REPUBLIC WITH A VIEW TO RESUMING ENROLLMENT PROCESS IN OTHER TWO CLINICAL CENTERS.OUR AIM WAS TO RESUME IMPLANTS WITHIN FRAMEWORK OF PIVOTAL STUDY BY END OF Q3 OF 2019.AIMS TO RAPIDLY FINALIZE ENROLLMENT OF SECOND PATIENT COHORT IN PIVOTAL STUDY IN KAZAKHSTAN AND CZECH REPUBLIC.AIMS TO SUBMIT FULL CLINICAL FILE TO DEKRA CERTIFICATION BODY WITH A VIEW TO OBTAINING CE MARKING IN 2020.  Full Article

Carmat End-Dec. Cash And Marketable Cash Instruments Of EUR 25.2 Million
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - CARMAT SA ::PRESENTS POSITIVE INTERIM RESULTS OF THE FIRST PART OF ITS PIVOTAL STUDY.CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR 25.2 MILLION AT DECEMBER 31, 2018.70% OF PATIENTS IN THIS FIRST COHORT REACHED STUDY'S PRIMARY ENDPOINT.DATA CONFIRM BIOCOMPATIBILITY OF CARMAT PROSTHESIS.COMPANY IS CURRENTLY VALIDATING ADDITIONAL CLINICAL CENTERS IN TWO MORE COUNTRIES IN ORDER TO RAPIDLY COMPLETE ENROLLMENT OF SECOND PATIENT COHORT AND SUBMIT CE MARKING DOSSIER IN EARLY 2020.CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR 25.2 MILLION AT DECEMBER 31, 2018, VERSUS EUR 44.0 MILLION AT JUNE 30, 2018.CASH BURN OF EUR 19.7 MILLION OVER PERIOD.ACCESS TO AN ADDITIONAL EUR 24.2 MILLION OF FINANCING.  Full Article

Carmat Appoints Pascale D’Arbonneau As Chief Financial Officer
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - CARMAT SA ::CARMAT ANNOUNCES THE APPOINTMENT OF PASCALE D’ARBONNEAU AS CHIEF FINANCIAL OFFICER.  Full Article

BRIEF-Carmat Announces First Implantation Of Its Total Artificial Heart In Denmark

* CARMAT ANNOUNCES THE FIRST IMPLANTATION OF ITS TOTAL ARTIFICIAL HEART IN DENMARK